Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions are flooding the market. From cardiology and imaging to oncology and primary care, clinicians are being asked to evaluate algorithms that promise earlier detection, better accuracy, and more efficient care. Many of these tools are technically impressive. Some are FDA-cleared. A few even come with early clinical data. Yet only a relatively small number have become part of routine clinical practice.
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Related Articles
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.{post_date: F d, Y}
Turning ECG Data into Actionable Insight with AI
For decades, the ECG has been a fundamental yet relatively limited diagnostic tool in cardiovascular medicine. However, AI-enabled technologies are shifting this paradigm by extracting layers of hidden biological signals…{post_date: F d, Y}
Profile of a Founder: Venky Soundarajan
The Tech Tribune: An exclusive Tech Tribune Q&A with Venky Soundararajan (co-founder and CSO) of nference, which was honored in our: 2022, 2021, 2020 Best Tech Startups in Cambridge.{post_date: F d, Y}
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the…{post_date: F d, Y}